The Role of Interleukin-10 in the Pathogenesis and Treatment of a Spinal Cord Injury
-
Published:2024-01-09
Issue:2
Volume:14
Page:151
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Patilas Christos1, Varsamos Iordanis1ORCID, Galanis Athanasios1, Vavourakis Michail1ORCID, Zachariou Dimitrios1ORCID, Marougklianis Vasileios1, Kolovos Ioannis1, Tsalimas Georgios1, Karampinas Panagiotis1ORCID, Kaspiris Angelos1ORCID, Vlamis John1, Pneumaticos Spiros1
Affiliation:
1. 3rd Department of Orthopaedic Surgery, National & Kapodistrian University of Athens, KAT General Hospital, 14561 Athens, Greece
Abstract
Spinal cord injury (SCI) is a devastating condition that often leads to severe and permanent neurological deficits. The complex pathophysiology of an SCI involves a cascade of events, including inflammation, oxidative stress, and secondary injury processes. Among the myriad of molecular players involved, interleukin-10 (IL-10) emerges as a key regulator with the potential to modulate both the inflammatory response and promote neuroprotection. This comprehensive review delves into the intricate interplay of IL-10 in the pathogenesis of an SCI and explores its therapeutic implications in the quest for effective treatments. IL-10 has been found to regulate inflammation, oxidative stress, neuronal apoptosis, and glial scars after an SCI. Its neuroprotective properties have been evaluated in a plethora of animal studies. IL-10 administration, either isolated or in combination with other molecules or biomaterials, has shown neuroprotective effects through a reduction in inflammation, the promotion of tissue repair and regeneration, the modulation of glial scar formation, and improved functional outcomes. In conclusion, IL-10 emerges as a pivotal player in the pathogenesis and treatment of SCIs. Its multifaceted role in modulating inflammation, oxidative stress, neuronal apoptosis, glial scars, and neuroprotection positions IL-10 as a promising therapeutic target. The ongoing research exploring various strategies for harnessing the potential of IL-10 offers hope for the development of effective treatments that could significantly improve outcomes for individuals suffering from spinal cord injuries. As our understanding of IL-10′s intricacies deepens, it opens new avenues for innovative and targeted therapeutic interventions, bringing us closer to the goal of alleviating the profound impact of SCIs on patients’ lives.
Subject
Clinical Biochemistry
Reference81 articles.
1. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 18, 56–87. 2. Trauma: Spinal Cord Injury;Eckert;Surg. Clin. N. Am.,2017 3. Anjum, A., Yazid, M.D., Fauzi Daud, M., Idris, J., Ng, A.M.H., Selvi Naicker, A., Ismail, O.H.R., Athi Kumar, R.K., and Lokanathan, Y. (2020). Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms. Int. J. Mol. Sci., 21. 4. Traumatic spinal cord injury;Ahuja;Nat. Rev. Dis. Prim.,2017 5. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury;Davies;Arch. Phys. Med. Rehabil.,2007
|
|